Heart drug may stop common complication after esophageal cancer surgery
NCT ID NCT06067438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the drug amiodarone after minimally invasive esophageal cancer surgery can prevent a common complication called atrial fibrillation (an irregular, often rapid heart rhythm). About 90 adults having this surgery will be randomly assigned to receive either amiodarone or standard care. The goal is to see if the drug reduces the risk of developing this heart rhythm problem in the first week after surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- A tiny neck implant could catch Stroke-Causing clots before they reach the brain
- Can surgery for stomach or esophageal cancer cloud the mind?
- Virtual patients could revolutionize cancer drug testing